scholarly journals Metabolic syndrome is inversely related to soluble receptor for advanced glycation end products: a study in mother-infant pairs

2011 ◽  
Vol 27 (2) ◽  
pp. 132-140
Author(s):  
K. Klenovicsova ◽  
P. Boor ◽  
J. Hrachova ◽  
K. Furkova ◽  
K. Sebekova
Keyword(s):  
Metabolic Syndrome ◽  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Mohamed Haddad ◽  
Ines Knani ◽  
Hsan Bouzidi ◽  
Olfa Berriche ◽  
Mohamed Hammami ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Advanced Glycation End Products ◽  
Plasma Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Control Subjects ◽  
Glycation End Products ◽  
End Products ◽  
Carboxymethyl Lysine

Metabolic syndrome (MetS) is considered one of the most important public health problems. Several and controversial studies showed that the role of advanced glycation end products (AGEs) and their receptor in the development of metabolic syndrome and therapeutic pathways is still unsolved. We have investigated whether plasma pentosidine, carboxymethyl-lysine (CML), and soluble receptor for advanced glycation end products (sRAGE) levels were increased in patients with MetS and the effect of metformin in plasma levels of pentosidine, CML, and sRAGE. 80 control subjects and 86 patients were included in this study. Pentosidine, CML, and sRAGE were measured in plasma by enzyme-linked immunosorbent assay (ELISA). Plasma pentosidine, CML, and sRAGE levels were significantly increased in patients compared to control subjects (P<0.001,P<0.001, andP=0.014, resp.). Plasma levels of pentosidine were significantly decreased in patients who received metformin compared to untreated patients (P=0.01). However, there was no significant difference between patients treated with metformin and untreated patients in plasma CML levels. Plasma levels of sRAGE were significantly increased in patients who received metformin and ACE inhibitors (P<0.001andP=0.002, resp.). However, in a multiple stepwise regression analysis, pentosidine, sRAGE, and drugs treatments were not independently associated. Patients with metabolic syndrome showed increased levels of AGEs such as pentosidine and CML. Metformin treatment showed a decreased level of pentosidine but not of CML. Therapeutic pathways of AGEs development should be taken into account and further experimental andin vitrostudies merit for advanced research.

scholarly journals Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: The Northern Manhattan Study

Metabolism ◽  
2014 ◽  
Vol 63 (9) ◽  
pp. 1125-1130 ◽  
Author(s):  
Barry I. Hudson ◽  
Chuanhui Dong ◽  
Hannah Gardener ◽  
Mitchell S.V. Elkind ◽  
Clinton B. Wright ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Advanced Glycation End Products ◽  
Serum Levels ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria

2015 ◽  
Vol 13 (2) ◽  
pp. 259-264
Author(s):  
Huan Zheng ◽  
Lingyan Yuan ◽  
Nanzi Xie ◽  
Huifeng Xu ◽  
Xiaoyun Xie ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Association of Dietary Advanced Glycation End Products with Metabolic Syndrome in Young Mexican Adults

Medicines ◽  
2018 ◽  
Vol 5 (4) ◽  
pp. 128 ◽  
Author(s):  
Kenny Mendoza-Herrera ◽  
Celia Aradillas-García ◽  
Miguel Mejía-Diaz ◽  
Jorge Alegría-Torres ◽  
Ma. Garay-Sevilla ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Family History ◽  
Energy Intake ◽  
Advanced Glycation End Products ◽  
Fasting Glucose ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
History Of ◽  
Mexican Adults

Background: Consumption of dietary advanced glycation end products is linked to metabolic syndrome. The objective was to describe the association between dietary advanced glycation end products intake and metabolic syndrome in young Mexican adults. Methods: The present was a cross-sectional study in 126 Mexican adults 18–35 years old evaluating metabolic syndrome through the harmonized criteria. Macronutrients and dietary advanced glycation end products intake were estimated through three 24-hour dietary recalls and food composition tables. Association between metabolic syndrome and high advanced glycation end products intake (≥10,000 kU/day) was evaluated through three logistic regression models adjusted by sex, age, family history of cardiometabolic diseases and energy intake. Results: Subjects with a higher advanced glycation end products intake were more likely to have impaired fasting glucose (OR: 4.91, 95% CI 1.29–18.60, p < 0.05) and metabolic syndrome (OR: 2.67, 95% CI 0.96–7.44, p = 0.059) than those participants with low consumption of these products after adjustment of sex, age, family history of cardiovascular disease and energy intake. Conclusions: High intake of dietary advanced glycation end products was significantly associated with impaired fasting glucose and marginally with metabolic syndrome in young Mexican adults regardless of sex, age, family history of cardiovascular disease and energy intake.

Relation of Soluble Receptor for Advanced Glycation End Products to Predict Mortality in Patients With Chronic Heart Failure Independently of Seattle Heart Failure Score

2011 ◽  
Vol 107 (6) ◽  
pp. 938-944 ◽  
Author(s):  
Sergio Raposeiras-Roubín ◽  
Bruno K. Rodiño-Janeiro ◽  
Lilian Grigorian-Shamagian ◽  
María Moure-González ◽  
Ana Seoane-Blanco ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Louise J. N. Jensen ◽  
Allan Flyvbjerg ◽  
Mette Bjerre
Keyword(s):  
Acute Coronary Syndrome ◽  
Advanced Glycation End Products ◽  
Acute Ischemia ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Coronary Syndrome ◽  
Potential Biomarker ◽  
Glycation End Products ◽  
End Products ◽  
Artery Disease

The receptor of advanced glycation end products (RAGE) and its ligands are linked to the pathogenesis of coronary artery disease (CAD), and circulating soluble receptor of advanced glycation end products (sRAGE), reflecting the RAGE activity, is suggested as a potential biomarker. Elevated sRAGE levels are reported in relation to acute ischemia and this review focuses on the role of sRAGE as a biomarker for the acute coronary syndrome (ACS). The current studies demonstrated that sRAGE levels are elevated in relation to ACS, however during a very narrow time period, indicating that the time of sampling needs attention. Interestingly, activation of RAGE may influence the pathogenesis and reflection in sRAGE levels in acute and stable CAD differently.

Sign in / Sign up

Export Citation Format

Share Document